Verified Nov 2026
Batteries & E-Mobility
·
Atlanta, Georgia
·
Since 2008
Axion BioSystems is a life science tools company headquartered in Atlanta, Georgia, founded in 2008 and currently estimated at 100-200 employees with revenue in the $10-50M range. It is privately held and makes live-cell analysis platforms, including Maestro microelectrode array systems for real-time, label-free monitoring of cell activity. Its products serve drug discovery, neurotoxicity screening, cardiac safety profiling, and research in academia, biopharma, and clinical research organizations.
Axion BioSystems at a glance
Revenue
$10-50M
Est. band
Employees
100-200
Founded
2008
Headquarters
Atlanta, Georgia
Import activity
3
Industries
Automotive
Electric Vehicles
Electronics
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
3
Named foreign suppliers
1
Top origins
Taiwan
Shared foreign counterparties do not establish that these companies buy from Axion BioSystems.
What this tells a buyer
Axion BioSystems announced in February 2026 that its Maestro MEA platform was used for the first stem cell cardiac safety assay in the FDA ISTAND program, according to the company's website.
The company offers Bioelectronic Assays built on microelectrode arrays and impedance-based methods, along with AI-powered imaging, automated cell counting tools, and assay kits.
Axion BioSystems is privately held and reports no certifications in the record, and it acquired high-density CMOS microelectrode array technology from CytoTronics in January 2026.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Axion BioSystems is a life science tools company headquartered in Atlanta, Georgia, founded in 2008 and currently estimated at 100-200 employees with revenue in the $10-50M range. It is privately held and makes live-cell analysis platforms, including Maestro microelectrode array systems for real-time, label-free monitoring of cell activity. Its products serve drug discovery, neurotoxicity screening, cardiac safety profiling, and research in academia, biopharma, and clinical research organizations.
At a glance
Attribute | Detail |
|---|---|
Founded | 2008 |
Headquarters | Atlanta, Georgia |
Employees | 100-200 |
Revenue | $10-50M (estimated) |
Primary capability | Batteries & E-Mobility |
What Axion BioSystems makes
The company offers Bioelectronic Assays built on microelectrode arrays and impedance-based methods, along with AI-powered imaging, automated cell counting tools, and assay kits.
Products and capabilities described on the company's own site include Semiconductor, Electronics, Emissions (source: axionbiosystems.com).
Trade and customs footprint
Axion BioSystems announced in February 2026 that its Maestro MEA platform was used for the first stem cell cardiac safety assay in the FDA ISTAND program, according to the company's website. US customs bill-of-lading records list 3 inbound shipments across 1 foreign suppliers, with top origins including Taiwan.
Latest developments
2026-11-02 — Axion BioSystems Introduces Synexus, Bringing Single-Cell Resolution to High-Throughput Functional Cell Analysis (businesswire.com)
2026-08-19 — Axion BioSystems Announces BioLamina Distribution Agreement to Support Organoid Research | Axion Biosystems (axionbiosystems.com)
2026-02-18 — Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program | Axion Biosystems (axionbiosystems.com)
2026-01-24 — Axion BioSystems Buys CytoTronics’ High Density CMOS Microelectrode Array Platform For Drug Discovery (pulse2.com)
2026-01-22 — Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronics | Axion Biosystems (axionbiosystems.com)
2025-08-29 — Axion BioSystems Maestro Pro 768 Service Maintenance Contract (sweetspotgov.com)
Company details
Axion BioSystems is privately held and reports no certifications in the record, and it acquired high-density CMOS microelectrode array technology from CytoTronics in January 2026. Axion BioSystems was founded in 2008, has an estimated 100-200 employees, and is headquartered in Atlanta, Georgia.
Frequently asked questions
What does Axion BioSystems make?
Axion BioSystems is a life science tools company headquartered in Atlanta, Georgia, founded in 2008 and currently estimated at 100-200 employees with revenue in the $10-50M range. It is privately held and makes live-cell analysis platforms, including Maestro microelectrode array systems for real-time, label-free monitoring of cell activity. Its products serve drug discovery, neurotoxicity screening, cardiac safety profiling, and research in academia, biopharma, and clinical research organizations.
Where is Axion BioSystems headquartered?
Axion BioSystems is headquartered in Atlanta, Georgia (171 17th St NW, Atlanta, Georgia, 30363-1028).
When was Axion BioSystems founded?
Axion BioSystems was founded in 2008.
How big is Axion BioSystems?
Axion BioSystems has an estimated 100-200 employees, with revenue in the $10-50M range (estimated).
Does Axion BioSystems import from overseas suppliers?
US customs bill-of-lading records show 3 inbound shipments for Axion BioSystems, with top origins including Taiwan.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.